|
Windtree Therapeutics Inc (NASDAQ: WINT) |
|
Windtree Therapeutics Inc
WINT's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Windtree Therapeutics Inc's sales fell
in the first quarter of 2025 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 11.96 %
Windtree Therapeutics Inc faced net loss in contrast to the net income a year ago in first quarter of 2025
• More on WINT's Growth
|
|
Windtree Therapeutics Inc realized a net loss in trailing twelve months.
Windtree Therapeutics Inc realized cash reduction of $ -0 per share in trailing twelve-month period. |
Company |
-0 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.2.
• More on WINT's Valuation
|
|
|
|
|
Windtree Therapeutics Inc realized net loss in trailing twelve months.
Windtree Therapeutics Inc realized cash outflow of $ -0per share in trailing twelve-month period. |
Company |
-0 |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.2.
Windtree Therapeutics Inc Price to Book Ratio is at 63.16 lower than Industry Avg. of 1878.65. and higher than S&P 500 Avg. of 0.01
• More on WINT's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com